

**ADOCIA**

innovative medicine  
for everyone, everywhere



## PRESS RELEASE

# Adocia Initiates ADR program (American Deposit Receipt) in the United States

## ADRs trading on the OTC Markets Under the Symbol ADOCY

**Lyon, France, May 27, 2014** - Adocia (Euronext Paris: FR0011184241 – ADOC) announced today that it has initiated an official ADR (American Depositary Receipt) program for the US market.

The Adocia ADRs are negotiable securities in US Dollars representing ordinary shares of Adocia stock, according to a 1 ADR to 1 share ratio<sup>1</sup>. They will be traded on the US OTC (Over the Counter) market under the Ticker Symbol: ADOCY. Transactions in US ADRs will be in addition to those currently made on Euronext. The program is being managed by Bank of New York Mellon.

*"We are very pleased to launch this ADR program in the U.S. which has the largest group of healthcare investors worldwide" stated Gérard Soula, President and CEO of Adocia. "Over the past year, we have endeavored to generate interest in Adocia within this market and raise our profile in the U.S. It is at the request of many investors that we are implementing this ADR program."*

### About Adocia:

#### **To be a global leader in the delivery of insulins and therapeutic proteins**

Adocia is clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia's proprietary BioChaperone<sup>®</sup> technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

Adocia has successfully completed two Phase I and II studies of a fast-acting human insulin formulation, two Phase I and II studies of an ultra-fast-acting insulin lispro and a Phase I/II of a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Dose-escalation Phase IIa studies of all three products are scheduled for 2014.

The company has also obtained positive results in a Phase I/II study of a diabetic-foot-ulcer-healing product based on PDGF-BB (Platelet-Derived Growth-Factor BB). A phase III clinical trial dossier has been filed with Indian regulatory authorities, and the trial is expected to start in 2014.

<sup>1</sup>Unlike centralized stock exchange market, OTC market have never had a physical location. They are less formal, though often well organized and the trading networks are focused on one or more brokers

Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

### **Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is remarkably efficient in delivering active compounds into cancer cells. This new platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

### **“Innovative medicine for everyone, everywhere”**

Adocia’s therapeutic innovations aim at providing solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and its share price is included in the Next Biotech index.

American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY.

For more information, visit [www.adocia.com](http://www.adocia.com)

### **Contact**

Gerard Soula - [contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)  
Chairman and CEO, Adocia  
Tel.: +33 472 610 610



### **Press Relations**

#### **ALIZE RP**

Caroline Carmagnol /Sayuli Nishioka  
[caroline@alizerp.com](mailto:caroline@alizerp.com) – [sayuli@alizerp.com](mailto:sayuli@alizerp.com)  
Tel.: +33 170 225 390

### **Disclaimer**

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document registered by the Autorite des marches financiers on April 24, 2014 under number R.14-020 (a copy of which is available on <http://www.adocia.com>) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.